Alembic Pharma Financial Statements

Alembic Pharma (APLLTD) reported revenue of ₹67.15B in FY2025 with net income of ₹5.82B. Total assets stood at ₹77.73B and free cash flow was -₹4.76B.

Alembic Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		54.03B	53.56B	56.55B	62.57B	67.15B
Cost of Rev. Cost of Revenue		-12.57B	-14.46B	-17.09B	-17.15B	-17.93B
Gross Profit		41.46B	39.10B	39.47B	45.42B	49.21B
SGA Sales, General & Admin		-25.78B	-29.85B	-32.35B	-35.80B	-38.70B
Op. Income Operating Income		13.84B	6.38B	4.36B	6.89B	7.72B
PBT Profit Before Tax		13.68B	6.25B	3.55B	6.33B	7.06B
Net Income		11.78B	5.21B	3.42B	6.16B	5.82B
Dil. Shares Diluted Shares		193.74M	196.56M	196.56M	196.56M	196.57M
Diluted EPS		60.81	26.50	17.40	31.33	29.68

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Alembic Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Alembic Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		25.78B	28.61B	29.10B	30.79B	40.88B
Non-curr. assets Total non-current assets		41.31B	42.61B	32.73B	33.67B	36.85B
Total assets		67.09B	71.22B	61.83B	64.46B	77.73B
Curr. liabilities Total current liabilities		12.81B	17.17B	16.37B	14.55B	24.12B
Non-curr. liab. Total non-current liabilities		3.61B	1.68B	1.75B	1.72B	1.71B
Total liabilities		16.42B	18.85B	18.12B	16.27B	25.83B
Total equity		50.67B	52.38B	43.70B	48.18B	51.90B
Total liab. & eq. Total liabilities & equity		67.09B	71.22B	61.83B	64.46B	77.73B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Alembic Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Alembic Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		13.68B	6.25B	3.55B	6.32B	7.07B
Operating CF Cash flow Operating Activities		14.63B	5.52B	7.24B	8.03B	879.70M
Capex Investments in PPE		-6.60B	-4.26B	-4.43B	-3.27B	-5.64B
Investing CF Cash flow Investing Activities		-8.39B	-3.72B	-4.48B	-3.21B	-5.68B
Dividend Paid		0	-2.75B	-1.97B	-1.57B	-2.16B
Financing CF Cash flow Financing Activities		-5.97B	-2.17B	-2.62B	-4.38B	4.44B
Cash (start) Cash at beginning of period		718.40M	980.60M	610.90M	754.80M	1.20B
Cash (end) Cash at end of period		980.60M	610.90M	754.80M	1.20B	834.80M
FCF Free Cash Flow		8.04B	1.27B	2.81B	4.76B	-4.76B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Alembic Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025